PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 864387

[New methods of coagulation analysis using chromogenic substrates].

I Witt
View original source ↗Export metadata ↓

Abstract

The available assay systems for the determination of coagulation factors based on clotting methods are unsatisfactory, despite efforts to stabilize and to standardize them. Analysis by means of chromogenic peptide substrates offers new possiblities for routine diagnostics, and for fundamental research. The development of these new methods, however, is at an early stage.

Explore related subjects

Blood Coagulation FactorsBlood Coagulation TestsFemaleHematologic DiseasesHeparinHumansHydrolysisKallikreinsLiver DiseasesMalePeptidesPlatelet AggregationEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

I Witt. 1977. [New methods of coagulation analysis using chromogenic substrates].. https://pubmed.ncbi.nlm.nih.gov/864387/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.

Platelet clots resist fibrinolysis by plasminogen activators. We hypothesized that platelet factor XIII may enhance the fibrinolytic resistance of platelet-rich clots by catalyzing the crosslinking of alpha 2-antiplasmin (alpha 2AP) to fibrin. Analysis of plasma clot structure by polyacrylamide gel electrophoresis and immunoblotting revealed accelerated alpha 2AP-fibrin crosslinking in platelet-rich compared with platelet-depleted plasma clots. A similar study of clots formed with purified fibrinogen (depleted of factor XIII activity), isolated platelets, and specific factor XIII inhibitors indicated that this accelerated crosslinking was due to the catalytic activity of platelet factor XIII. Moreover, when washed platelets were aggregated by thrombin, there was evidence of platelet factor XIII-mediated crosslinking between platelet alpha 2AP and platelet fibrin(ogen). Specific inhibition (by a monoclonal antibody) of the alpha 2AP associated with washed platelet aggregates accelerated the fibrinolysis of the platelet aggregate. Thus in platelet-rich plasma clots, and in thrombin-induced platelet aggregates, platelet factor XIII actively formed alpha 2AP-fibrin crosslinks, which appeared to enhance the resistance of platelet-rich clots to fibrinolysis.

Blood Coagulation Factors↗